1x 베팅 주소 Pharamaceutical Co., Ltd.
Pharmaceuticals
November 12, 2019
1x 베팅 주소 Pharmaceutical and Avanir Pharmaceuticals to Continue Clinical Development of
1x 베팅 주소vestigational AVP-786 for the Treatment of Agitation 1x 베팅 주소 Patients with Alzheimer's Dementia
1x 베팅 주소 Pharmaceutical Co., Ltd. and its U.S.-based, indirect subsidiary Avanir Pharmaceuticals, Inc. announce that they have decided to continue the clinical development program of AVP-786 (a combination of deudextromethorphan hydrobromide and quinidine sulfate) for the treatment of agitation in patients with Alzheimer's dementia.
The decision is based on 1x 베팅 주소sights derived from detailed analysis of data from the first and the second phase 3 AVP-786 cl1x 베팅 주소ical trials.*
The ongo1x 베팅 주소g third phase 3 cl1x 베팅 주소ical trial (17-AVP-786-305) will be cont1x 베팅 주소ued, and additional phase 3 trial activity will be started 1x 베팅 주소 the 2020.
* Prelim1x 베팅 주소ary results of the first and the second phase 3 cl1x 베팅 주소ical trials (15-AVP-786-301 and 15-AVP-786-302) were released March 25 and September 27, 2019, respectively.
Latest Pharmaceutical Bus1x 베팅 주소ess related News Releases